PTN
NASD Palatin Technologies, Inc.$6.02 ↑ +0.00 (+0.00%) Trading Up from the previous close of $6.02, $0.91 below the day’s high of $6.93
- YTD change
- -60.86%
- vs 20-day SMA
- -34.63%
- vs 200-day SMA
- -58.94%
Price ranges
Price & Performance
-14.88 (-71.20%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 80.6% away from all-time highs of $31.00
- PTN is down 61% since the beginning of the year
- PTN is down 45% over the past 12 months
- PTN is down 42% over the past 1 month
- 10% of all PTN investors are betting against PTN
PTN reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -45.5%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -33.19%
- vs 8-day SMA
- -28.32%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Princeton, NJ.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
